Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hypoxia Inducible Factor 2α (HIF-2α)”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04489771
What this trial is testing

Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 154
Large-scale testing (Phase 3)Active Not RecruitingNCT04195750
What this trial is testing

Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 755
Testing effectiveness (Phase 2)Ended earlyNCT05119335
What this trial is testing

NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Who this might be right for
ccRCCClear Cell Renal Cell CarcinomaKidney Cancer+14 more
NiKang Therapeutics, Inc. 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05239728
What this trial is testing

Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,800
Testing effectiveness (Phase 2)Active Not RecruitingNCT05468697
What this trial is testing

Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 60
Early research (Phase 1)Active Not RecruitingNCT05030506
What this trial is testing

Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 45